Crosslink Therapeutics files Form D for $5.5 million offering
The Boston-based pharmaceutical company reported selling all of a $5.5 million offering to eight investors under a Rule 506(b) exemption.
SEC filing
Latest
1 story
Sign inSign in1 story
The Boston-based pharmaceutical company reported selling all of a $5.5 million offering to eight investors under a Rule 506(b) exemption.
SEC filing